Your browser is no longer supported. Please, upgrade your browser.
Settings
ADAP Adaptimmune Therapeutics plc daily Stock Chart
ADAP [NASD]
Adaptimmune Therapeutics plc
Index- P/E- EPS (ttm)-1.37 Insider Own0.25% Shs Outstand103.99M Perf Week-18.58%
Market Cap382.68M Forward P/E- EPS next Y-1.10 Insider Trans-62.01% Shs Float11.26M Perf Month172.59%
Income-144.00M PEG- EPS next Q-0.32 Inst Own71.90% Short Float13.58% Perf Quarter311.63%
Sales1.90M P/S201.41 EPS this Y-23.00% Inst Trans0.01% Short Ratio0.80 Perf Half Y15.72%
Book/sh1.40 P/B2.63 EPS next Y19.10% ROA-57.90% Target Price5.50 Perf Year-21.54%
Cash/sh0.99 P/C3.72 EPS next 5Y1.00% ROE-71.90% 52W Range0.71 - 6.00 Perf YTD206.67%
Dividend- P/FCF- EPS past 5Y-56.20% ROI-33.60% 52W High-31.83% Beta2.21
Dividend %- Quick Ratio3.90 Sales past 5Y178.50% Gross Margin- 52W Low476.87% ATR0.53
Employees430 Current Ratio3.90 Sales Q/Q-99.50% Oper. Margin- RSI (14)73.09 Volatility10.54% 20.62%
OptionableYes Debt/Eq0.00 EPS Q/Q-839.00% Profit Margin- Rel Volume0.99 Prev Close3.68
ShortableYes LT Debt/Eq0.00 EarningsFeb 05 BMO Payout- Avg Volume1.92M Price4.09
Recom2.40 SMA2051.90% SMA50135.49% SMA20068.25% Volume1,343,246 Change11.14%
Aug-02-19Downgrade Guggenheim Buy → Neutral
May-31-19Initiated ROTH Capital Buy
May-30-19Resumed Citigroup Buy
May-07-19Downgrade SVB Leerink Outperform → Mkt Perform $12 → $5
Mar-17-17Initiated Wells Fargo Market Perform
Oct-24-16Downgrade BofA/Merrill Neutral → Underperform
Sep-30-16Initiated Raymond James Outperform $16
Feb-25-16Initiated Citigroup Buy $15
Jun-01-15Initiated Leerink Partners Outperform $24
Jun-01-15Initiated Guggenheim Buy
Jun-01-15Initiated BofA/Merrill Neutral
Jan-24-20 04:30PM  Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares GlobeNewswire
Jan-22-20 01:18PM  Philadelphia cell therapy company prices $84M public stock offering American City Business Journals
08:48AM  Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares GlobeNewswire
08:25AM  The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings Benzinga
06:48AM  Top Ranked Momentum Stocks to Buy for January 22nd Zacks
Jan-21-20 04:08PM  Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares GlobeNewswire -8.41%
Jan-17-20 12:00PM  What Makes Adaptimmune Therapeutics PLC (ADAP) a New Buy Stock Zacks
Jan-15-20 08:22AM  The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance Benzinga +9.90%
Jan-14-20 12:29PM  After a Massive Gain, Is There Still Room for Adaptimmune (ADAP) Stock to Soar? TipRanks
07:55AM  The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug Benzinga
02:08AM  Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies GlobeNewswire
Jan-13-20 08:30AM  Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership GlobeNewswire +200.00%
02:00AM  Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications GlobeNewswire
Dec-30-19 05:25AM  Adaptimmune Therapeutics (NASDAQ:ADAP) Will Have To Spend Its Cash Wisely Simply Wall St. -15.94%
Dec-16-19 05:45AM  Is Adaptimmune Therapeutics plc (ADAP) Going To Burn These Hedge Funds ? Insider Monkey +9.02%
Dec-03-19 02:20PM  Adaptimmune gets FDA designation to accelerate development of cancer therapy American City Business Journals +5.88%
08:30AM  Regenerative Medicine Advanced Therapy Designation Granted by FDA to ADPA2M4 for the Treatment of Synovial Sarcoma GlobeNewswire
Nov-17-19 11:40AM  Edited Transcript of ADAP earnings conference call or presentation 6-Nov-19 1:00pm GMT Thomson Reuters StreetEvents
Nov-16-19 02:00AM  Updated Data from Phase 1 ADP-A2M4 Trial Demonstrating Continued Clinical Benefit for People with Synovial Sarcoma GlobeNewswire
Nov-06-19 07:30AM  Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update GlobeNewswire -16.35%
Nov-01-19 08:00AM  Adaptimmune to Report Third Quarter 2019 Financial Results and Business Update on Wednesday, November 6, 2019 GlobeNewswire +9.10%
Oct-31-19 01:52PM  Is Adaptimmune Therapeutics plc (ADAP) Is Burning These Hedge Funds Insider Monkey
06:09AM  Do Directors Own Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares? Simply Wall St.
Oct-09-19 08:00AM  Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmunes Cell Therapies GlobeNewswire +6.93%
Oct-01-19 08:00AM  Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer GlobeNewswire -5.30%
Sep-30-19 08:45AM  Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO GlobeNewswire
Sep-16-19 06:41AM  Does The Adaptimmune Therapeutics plc (NASDAQ:ADAP) Share Price Fall With The Market? Simply Wall St.
Sep-10-19 09:01AM  Adaptimmune (ADAP) Gets Orphan Drug Status for T-cell Therapy Zacks +24.12%
Sep-09-19 08:00AM  United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4 GlobeNewswire +8.28%
Aug-27-19 02:11PM  Edited Transcript of ADAP earnings conference call or presentation 1-Aug-19 12:00pm GMT Thomson Reuters StreetEvents +6.99%
08:00AM  Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patients GlobeNewswire
Aug-16-19 11:23AM  What's in Store for Aytu BioScience's (AYTU) Q4 Earnings? Zacks +11.64%
Aug-01-19 10:24PM  Adaptimmune Therapeutics (ADAP) Q2 2019 Earnings Call Transcript Motley Fool -10.33%
07:15AM  New Executive Team Announced at Adaptimmune GlobeNewswire
07:15AM  Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update GlobeNewswire
Jul-29-19 04:05PM  Adaptimmune to Report Second Quarter 2019 Financial Results and Business Update on Thursday, August 1, 2019 GlobeNewswire
Jul-25-19 08:00AM  Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS GlobeNewswire -9.06%
Jul-22-19 08:00AM  Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center GlobeNewswire +11.62%
Jul-18-19 11:00AM  How Should Investors Feel About Adaptimmune Therapeutics plc's (NASDAQ:ADAP) CEO Pay? Simply Wall St.
08:00AM  Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGEA4 to Enhance Antitumor Responses GlobeNewswire
Jul-09-19 11:23AM  Athenex (ATNX) in Focus: Stock Moves 6.5% Higher Zacks
09:00AM  Adaptimmune Therapeutics PLC (ADAP) Upgraded to Strong Buy: Here's Why Zacks
Jun-29-19 05:37PM  Is Adaptimmune Therapeutics plc (ADAP) Going to Burn These Hedge Funds? Insider Monkey
Jun-27-19 02:54PM  Hedge Funds Piled Into This Stock Right Before Its 40% Ascend Insider Monkey
08:00AM  Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer GlobeNewswire
May-28-19 10:14AM  Those Who Purchased Adaptimmune Therapeutics (NASDAQ:ADAP) Shares A Year Ago Have A 72% Loss To Show For It Simply Wall St.
May-15-19 12:28PM  AdaptImmune partners to advance promising cancer immunotherapies American City Business Journals
08:00AM  Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products GlobeNewswire
May-06-19 07:30AM  Adaptimmune Reports First Quarter 2019 Financial Results GlobeNewswire -5.82%
07:00AM  Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors GlobeNewswire
May-02-19 07:00AM  Adaptimmune to Present Data Demonstrating that its Off-the-shelf Process Produces T-cells from Stem Cells that Respond to Cancer Targets with a SPEAR TCR at ASGCT Meeting GlobeNewswire
May-01-19 08:00AM  Adaptimmune to Provide Clinical and Business Update on Monday May 6th, 2019 GlobeNewswire
Apr-18-19 04:01PM  Adaptimmune Announces Oral Presentation of Allogeneic SPEAR T-cell Program at 2019 ASGCT Meeting GlobeNewswire
Apr-12-19 03:26PM  These 3 Falling Knives Are Expected to Outperform GuruFocus.com
Apr-02-19 08:00AM  Adaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research (AACR) Meeting GlobeNewswire +8.29%
Apr-01-19 08:00AM  Adaptimmune Presents Preclinical Data for its Next Generation SPEAR T-cell Targeting MAGE-A4 at the American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Mar-15-19 12:06PM  Does Adaptimmune Therapeutics plc (NASDAQ:ADAP) Have A Particularly Volatile Share Price? Simply Wall St.
Mar-06-19 12:15PM  Edited Transcript of ADAP earnings conference call or presentation 27-Feb-19 1:00pm GMT Thomson Reuters StreetEvents -8.66%
Feb-27-19 07:29AM  Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update GlobeNewswire
Feb-07-19 11:01AM  Should You Worry About Adaptimmune Therapeutics plcs (NASDAQ:ADAP) CEO Salary Level? Simply Wall St.
08:00AM  Adaptimmune to Report Fourth Quarter / Full Year 2018 Financial Results and Business Update on Wednesday, February 27, 2019 GlobeNewswire
Jan-28-19 09:38AM  Adaptimmune Therapeutics PLC (ADAP) Upgraded to Buy: Here's What You Should Know Zacks
Jan-08-19 04:30PM  Radius Exceeds 2018 Financial Guidance, Provides Updates Zacks
09:54AM  Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4 Zacks
Jan-07-19 07:30AM  Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews GlobeNewswire +5.94%
Jan-02-19 10:12AM  What Percentage Of Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares Do Insiders Own? Simply Wall St.
Dec-12-18 08:30AM  Adaptimmune Announces that Gwen Binder will leave in January 2019 GlobeNewswire -8.70%
Nov-28-18 08:30AM  Recent Analysis Shows Bellicum Pharmaceuticals, NetEase, Nice, Match Group, SpartanNash, and Adaptimmune Therapeutics Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-20-18 07:52AM  Edited Transcript of ADAP earnings conference call or presentation 6-Nov-18 1:00pm GMT Thomson Reuters StreetEvents
Nov-14-18 11:10AM  What You Must Know About Adaptimmune Therapeutics plcs (NASDAQ:ADAP) Financial Strength Simply Wall St. -5.83%
Nov-06-18 07:30AM  Adaptimmune Reports Third Quarter 2018 Financial Results and Business Update GlobeNewswire -8.42%
Oct-25-18 04:30PM  Adaptimmune to Report Third Quarter 2018 Financial Results and Business Update on Tuesday, November 6, 2018 GlobeNewswire
08:53AM  3 Beaten-Down Biotech Stocks: Can They Bounce Back? Motley Fool
07:29AM  Adaptimmune Therapeutics Worldwide Enters Oversold Territory Zacks
Oct-22-18 09:48AM  Adaptimmune's stock tumbles after cancer study results prompts price target cut MarketWatch -29.83%
Oct-20-18 10:45AM  Updated Data from Ongoing MAGE-A10 and MAGE-A4 Studies Presented at the 2018 ESMO Congress GlobeNewswire
Oct-17-18 07:20AM  Investor Expectations to Drive Momentum within Arsanis, Dynavax Technologies, Puma Biotechnology, Opko Health, Adaptimmune Therapeutics, and Codexis Discovering Underlying Factors of Influence GlobeNewswire
Oct-08-18 06:10PM  Data Updates from Ongoing MAGE-A10 Studies and MAGE-A4 Study to be presented at the European Society for Medical Oncology (ESMO) 2018 Congress GlobeNewswire -5.04%
Sep-19-18 07:30AM  3 Biotech Stocks That Big Investors Are Snatching Up Barrons.com
Sep-13-18 09:19AM  Should You Be Holding Adaptimmune Therapeutics plc (NASDAQ:ADAP) Right Now? Simply Wall St.
Sep-07-18 01:14PM  Adaptimmune Therapeutics plc Announces Closing of Registered Direct Offering of American Depositary Shares GlobeNewswire
Sep-05-18 07:30AM  Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares GlobeNewswire
Aug-24-18 10:37AM  Options Traders Expect Huge Moves in Adaptimmune (ADAP) Stock Zacks +11.05%
Aug-20-18 08:30AM  Investor Expectations to Drive Momentum within NEXEO SOLUTIONS, Altisource Portfolio Solutions S.A, Celestica, Star Bulk Carriers, Criteo S.A, and Adaptimmune Therapeutics Discovering Underlying Factors of Influence GlobeNewswire
Aug-15-18 07:30AM  Third Dosing Cohort to be initiated in MAGE-A4 SPEAR T-cell Basket Study After Favorable Review of Safety from One Billion Cell Dose Cohort GlobeNewswire
05:34AM  Edited Transcript of ADAP earnings conference call or presentation 2-Aug-18 12:00pm GMT Thomson Reuters StreetEvents
Aug-02-18 07:30AM  Adaptimmune Reports Second Quarter 2018 Financial Results and Business Update GlobeNewswire
06:00AM  Adaptimmune Therapeutics PLC Sponsored ADR to Host Earnings Call ACCESSWIRE
Jul-26-18 01:18PM  Adaptimmune to Report Second Quarter 2018 Financial Results and Business Update on Thursday August 2, 2018 GlobeNewswire
Jul-24-18 12:20PM  Why AdaptImmune collected $27.5M from GSK American City Business Journals
07:30AM  GSK and Adaptimmune Complete Transition of NY-ESO SPEAR T-cell Therapy Program to GSK GlobeNewswire
Jul-18-18 08:32AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:29AM  Adaptimmune Announces Favorable Review of Safety from One Billion Cell Dose Cohort in MAGE-A10 SPEAR T-cell Study and Initiation of Third Dosing Cohorts GlobeNewswire
Jun-27-18 10:52AM  Investors Are Undervaluing Adaptimmune Therapeutics plc (NASDAQ:ADAP) By 21.72% Simply Wall St.
Jun-11-18 07:30AM  Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Selfrenewing, and Capable of Persistent Anti-Tumor Effects GlobeNewswire
Jun-07-18 07:45AM  Complimentary Technical Snapshots on Adverum Biotechnologies and Three More Biotech Stocks ACCESSWIRE
Jun-04-18 07:30AM  Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO GlobeNewswire
07:30AM  Adaptimmune Announces First Patient to Receive One Billion Target Cell Dose after Positive Safety Data from Pilot Study with MAGE-A4 SPEAR T-cells GlobeNewswire
Jun-02-18 08:00AM  Updated Myxoid/Round Cell Liposarcoma Data with NY-ESO, Presented at ASCO Annual Meeting, Further Supports Promising Benefit: Risk Profile GlobeNewswire
Jun-01-18 07:30AM  Investor Expectations to Drive Momentum within SK Telecom Co., Adaptimmune Therapeutics, Fiat Chrysler Automobiles N.V, Achillion Pharmaceuticals, Pzena Investment Management, and Sasol Discovering Underlying Factors of Influence GlobeNewswire
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune's PRIME technology. It also has a co-development and co-commercialization agreement with Universal Cells, Inc to bring new stem-cell derived allogeneic T-Cell therapies to people with cancer. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Norry ElliotChief Medical OfficerJan 14Sale5.139114,6781,326Jan 15 08:03 PM
Bertrand William C JRChief Operating OfficerJan 14Sale5.132,39712,3083,605Jan 15 08:03 PM
Rawcliffe AdrianChief Executive OfficerJan 14Sale5.133,23616,6163,166Jan 15 08:01 PM
Lunger JohnChief Patient Supply OfficerJan 14Sale5.131,1445,8741,681Jan 15 08:02 PM
TAYTON-MARTIN HELEN KATRINAChief Business OfficerJan 13Sale4.50100,000450,0000Jan 15 08:02 PM
Noble JamesDirectorJan 13Sale4.67300,0001,400,0000Jan 15 08:01 PM
Rawcliffe AdrianChief Executive OfficerJan 06Sale1.205,9007,0805,804Jan 07 08:00 PM
Bertrand William C JRChief Operating OfficerJan 06Sale1.203,7314,4775,632Jan 07 08:01 PM
Lunger JohnChief Patient Supply OfficerJan 06Sale1.201,1481,3781,677Jan 07 08:01 PM
Amado RafaelPresident, R&DAug 06Sale2.0611,04322,74917,237Aug 07 09:00 PM
Noble JamesChief Executive OfficerMay 16Option Exercise0.141,773,100253,5531,773,100May 17 06:00 PM